Inventiva Logo

Inventiva

Clinical-stage biopharma developing oral therapies for fibrosis, oncology, & lysosomal disorders.

IVA | PA

Overview

Corporate Details

ISIN(s):
FR0013233012 (+2 more)
LEI:
969500I9Y690B3FZW590
Country:
France
Address:
50 RUE DE DIJON, 21121 DAIX
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Inventiva is a clinical-stage biopharmaceutical company focused on the development of novel oral small molecule therapies for diseases with significant unmet medical needs. The company's primary therapeutic areas include fibrosis, lysosomal storage disorders, and oncology. Its lead drug candidate, lanifibranor, is in a pivotal Phase III clinical trial for the treatment of non-alcoholic steatohepatitis (NASH) and has received Breakthrough Therapy Designation from the FDA. Another clinical candidate, odiparcil, targets mucopolysaccharidoses (MPS). Inventiva's pipeline is supported by a proprietary discovery engine with an extensive library of 240,000 compounds, a wholly-owned R&D facility, and expertise in targeting nuclear receptors and transcription factors.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-28 15:56
Regulatory News Service
Franchissement de seuils
French 120.1 KB
2025-11-28 15:42
Major Shareholding Notification
Franchissement de seuils
French 121.1 KB
2025-11-28 15:25
Major Shareholding Notification
Franchissement de seuils
French 110.0 KB
2025-11-13 15:21
ISS
Inventiva annonce les modalités définitives ainsi que l'extension de l'offre au…
French 353.4 KB
2025-11-13 15:21
ISS
Inventiva announces pricing of upsized public offering of approximately $150M o…
English 349.5 KB
2025-09-29 00:00
Interim Report
RFS
French 927.7 KB
2025-08-25 09:57
Major Shareholding Notification
Franchissement de seuil
French 114.0 KB
2025-08-25 09:56
Major Shareholding Notification
Franchissement de seuil
French 112.0 KB
2025-08-19 15:35
Major Shareholding Notification
Franchissement de seuil
French 116.8 KB
2025-08-19 15:32
Major Shareholding Notification
Franchissement de seuil
French 116.7 KB
2025-08-19 15:19
Major Shareholding Notification
Franchissement de seuil
French 116.1 KB
2025-08-12 15:57
Major Shareholding Notification
Franchissement de seuil
French 113.9 KB
2025-08-12 15:52
Major Shareholding Notification
Franchissements de seuil
French 121.6 KB
2025-08-11 15:14
Major Shareholding Notification
Franchissement de seuil
French 121.9 KB
2025-06-17 17:02
Major Shareholding Notification
Franchissement de seuils
French 113.4 KB

Automate Your Workflow. Get a real-time feed of all Inventiva filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Inventiva

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Inventiva via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-04-05 N/A Other Buy 10,000 N/A
2023-12-08 N/A Other Buy 15,000 N/A

Peer Companies

Qurient Co., Ltd. Logo
Biopharma developing novel drugs for cancer, inflammation, and infectious diseases.
South Korea
115180
Rafael Holdings, Inc. Logo
Invests in and develops novel therapeutics for cancer and rare diseases.
United States of America
RFL
RaQualia Pharma Inc. Logo
An R&D firm discovering novel small molecules for out-licensing to pharma partners.
Japan
4579
Recruit Holdings Co., Ltd. Logo
Global provider of HR tech (Indeed), staffing services, and business SaaS solutions.
Japan
6098
RELMADA THERAPEUTICS, INC. Logo
A clinical-stage biotech developing novel therapies for CNS diseases and oncology.
United States of America
RLMD
Renascience Inc. Logo
Develops innovative drugs and AI-powered medical devices for aging and hereditary diseases.
Japan
4889
Rentracks CO.,LTD. Logo
A pay-per-performance ad network with a closed ASP and comprehensive web consulting services.
Japan
6045
Replimune Group, Inc. Logo
Clinical-stage biotech developing oncolytic immunotherapies to treat a broad range of cancers.
United States of America
REPL
ReproCELL Incorporated Logo
Offers stem cell tech, gene editing & drug discovery services for preclinical/clinical research.
Japan
4978
RESEARCH FRONTIERS INC Logo
Develops and licenses smart glass tech for instant light, UV, and heat control.
United States of America
REFR

Talk to a Data Expert

Have a question? We'll get back to you promptly.